The (FSR) is proud to celebrate a major milestone for the FSR Sarc Fighter Podcast, which has officially surpassed ...

The Foundation for Sarcoidosis Research (FSR) is proud to celebrate a major milestone for the FSR Sarc Fighter Podcast, which ...

Infliximab and efzofitimod may be effective in pulmonary sarcoidosis and tofacitinib and adalimumab in cutaneous sarcoidosis.

Investigational interstitial lung disease (ILD) drug, efzofitimod, shows early signs of efficacy in patients with pulmonary ...

The Foundation for Sarcoidosis Research (FSR) is proud to announce the three recipients of the 2025 FSR Early Career Fellowship Grant: William Lippitt, PhD, (University of Colorado Anschutz Medical ...

Objective Owing to the paucity of data, this study aimed to investigate sex differences in clinical features and prognosis of patients with cardiac sarcoidosis (CS). Methods This study was a secondary ...

Sarcoidosis is a rare inflammatory disease characterized by granulomas—tiny clumps of inflammatory cells—that can form in one or more organs. 90% of patients living with sarcoidosis have lung ...

Groundbreaking research by the University of Sydney has identified a new brain protein involved in the development of Parkinson's disease and a way to modify it, paving the way for future ...

Correction to: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology ...